{"product_id":"sanofi-bcg-matrix","title":"Sanofi Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSanofi’s BCG Matrix snapshot highlights a mix of established Cash Cows from its mature vaccine and chronic care franchises, emerging Stars in specialty therapies, and potential Question Marks in niche biologics facing competitive pressure—insightful for allocating R\u0026amp;D and capital efficiently. This preview teases quadrant placements and strategic implications; purchase the full BCG Matrix for a complete, data-backed breakdown, actionable recommendations, and ready-to-use Word and Excel deliverables to guide investment and product decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDupixent (Dupilumab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of end 2025, Dupixent (dupilumab) is Sanofi’s premier Star, delivering €15.7 billion in 2025 sales and sustaining \u0026gt;25% annual growth.\u003c\/p\u003e\n\u003cp\u003eIt holds dominant market share in atopic dermatitis and asthma and is expanding into COPD and chronic spontaneous urticaria with multiple Phase III readouts in 2024–2025.\u003c\/p\u003e\n\u003cp\u003eDupixent generates massive cash but needs continued investment in label expansion and global commercialization to defend against emerging biologics and biosimilars.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALTUVIIIO (Hemophilia A)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALTUVIIIO (rFVIII, Hemophilia A) reached blockbuster status by end-2025 with €1.2 billion in annual sales and quarterly growth spikes over 90%, reflecting rapid uptake since launch.\u003c\/p\u003e \u003cp\u003eThe once-weekly extended half-life factor VIII has taken market share from conventional FVIII products by improving dosing frequency and adherence, driving estimated global share above 20% in 2025.\u003c\/p\u003e \u003cp\u003eAs a Star in Sanofi’s BCG matrix, ALTUVIIIO still requires heavy promotional spend—R\u0026amp;D and commercial investment remained high in 2025 to cement its standard-of-care position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBeyfortus (Nirsevimab)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBeyfortus (nirsevimab) is a Star for Sanofi in vaccines, posting €1.8 billion sales in 2025 and growing fastest in North America and Europe with rollouts in 35+ countries.\u003c\/p\u003e\n\u003cp\u003eIt dominates the RSV infant-protection market with first-to-market advantages in many regions and \u0026gt;60% share in hospital-protected infants in 2025.\u003c\/p\u003e\n\u003cp\u003eSanofi is investing \u0026gt;€1.2 billion through 2026 in manufacturing and global distribution to meet demand and convert Beyfortus toward Cash Cow status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAyvakit (Avapritinib)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAcquired in 2025 via Blueprint Medicines deal worth $9.5 billion, Ayvakit (avapritinib) became a Star for Sanofi in rare immunology and oncology by end-2025 with ~ $725 million pro-forma sales, leading systemic mastocytosis in a small but growing market.\u003c\/p\u003e\n\u003cp\u003eSanofi is funneling heavy investment to scale Ayvakit globally, boost diagnostic awareness, and anchor its hematology franchise, accepting high spend to capture long-term market share and diagnostics-driven uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 purchase: $9.5B\u003c\/li\u003e\n\u003cli\u003e2025 sales: ~$725M pro-forma\u003c\/li\u003e\n\u003cli\u003eIndication: systemic mastocytosis, high niche share\u003c\/li\u003e\n\u003cli\u003eStrategy: global rollout, diagnostic education, heavy capex\/OPEX\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNexviazyme (Pompe Disease)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNexviazyme has moved into the Star quadrant by taking share from Myozyme, posting double-digit growth to reach about €790–€810 million in 2024 sales, marking Sanofi’s lead in Pompe disease enzyme replacement therapy.\u003c\/p\u003e\n\u003cp\u003eSanofi still funds patient-switch programs and ongoing regulatory filings in emerging markets (India, BRICS) to sustain uptake and extend label access, supporting continued high-margin growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 sales ≈ €800M\u003c\/li\u003e\n\u003cli\u003eDouble-digit YoY growth (2023→2024)\u003c\/li\u003e\n\u003cli\u003eDisplaced Myozyme as market leader\u003c\/li\u003e\n\u003cli\u003eOngoing switch programs \u0026amp; filings in emerging markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech Blockbusters: Dupixent €15.7B, Beyfortus €1.8B, ALTUVIIIO €1.2B, growth leaders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Dupixent €15.7B (2025), \u0026gt;25% CAGR; ALTUVIIIO €1.2B (2025), ~20% global FVIII share; Beyfortus €1.8B (2025), \u0026gt;60% hospital protection share; Ayvakit $725M (pro-forma 2025); Nexviazyme ~€800M (2024), double-digit growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024\/25 Sales\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDupixent\u003c\/td\u003e\n\u003ctd\u003e€15.7B (2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;25% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eALTUVIIIO\u003c\/td\u003e\n\u003ctd\u003e€1.2B (2025)\u003c\/td\u003e\n\u003ctd\u003e~20% share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeyfortus\u003c\/td\u003e\n\u003ctd\u003e€1.8B (2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60% hospital\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAyvakit\u003c\/td\u003e\n\u003ctd\u003e$725M (2025)\u003c\/td\u003e\n\u003ctd\u003eniche leader\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNexviazyme\u003c\/td\u003e\n\u003ctd\u003e~€800M (2024)\u003c\/td\u003e\n\u003ctd\u003edouble-digit growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix analysis of Sanofi’s portfolio with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Sanofi BCG Matrix placing each business unit in a quadrant for swift portfolio decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLantus (Insulin Glargine)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLantus (insulin glargine) stays a Cash Cow for Sanofi, delivering stable cash flow in a mature diabetes market despite biosimilar pressure.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Lantus saw a temporary windfall from competitor shortages, kept high market share and generated over €1.7 billion in revenue that year.\u003c\/p\u003e\n\u003cp\u003eAs a legacy product it needs minimal promotion, letting Sanofi milk profits to fund R\u0026amp;D in immunology and vaccines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eToujeo (Insulin Glargine 300 U\/mL)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eToujeo (insulin glargine 300 U\/mL) is a Cash Cow for Sanofi, holding high market share in basal insulin—notably in Rest of the World—driving steady demand with low market growth.\u003c\/p\u003e\n\u003cp\u003eIt generates over €1.3 billion annually with high gross margins from established manufacturing and low R\u0026amp;D churn; 2024 margins reported near industry-normal levels.\u003c\/p\u003e\n\u003cp\u003eCash flows from Toujeo fund Sanofi’s corporate debt service and materially support the €10 billion 2025 share buyback program announced in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePoliomyelitis and Pertussis Vaccines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSanofi’s IPV (inactivated poliovirus vaccine) and acellular pertussis combos anchor its pediatric vaccine franchise, holding ~25–30% global market share in a mature market growing ~1–2% annually as of 2025.\u003c\/p\u003e\n\u003cp\u003eThese vaccines generate steady, predictable cash flow with low marketing spend—Sanofi reported €2.1bn pediatric vaccine sales in 2024—funding R\u0026amp;D into mRNA and recombinant platforms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFabrazyme (Fabry Disease)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFabrazyme (Fabry disease) is a cash cow for Sanofi, with global annual sales above €1.1 billion as of end‑2025 and a dominant market share in a mature enzyme‑replacement therapy market.\u003c\/p\u003e\n\u003cp\u003eLow incremental R\u0026amp;D and manufacturing needs keep margins high; strong patent protection and complex biologic manufacturing create high barriers to entry, preserving steady cash flow.\u003c\/p\u003e\n\u003cp\u003eSanofi channels these profits into higher‑risk oncology and neurology programs, funding pipeline spend without major new investment in Fabrazyme.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 sales: \u0026gt;€1.1 billion\u003c\/li\u003e\n\u003cli\u003eMature market: low growth, high profitability\u003c\/li\u003e\n\u003cli\u003eHigh barriers: patents + complex biologics manufacturing\u003c\/li\u003e\n\u003cli\u003eUses: fund oncology and neurology pipeline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlavix (Clopidogrel)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDespite patent expiry, Plavix (clopidogrel) stays a Cash Cow for Sanofi in select international markets—notably parts of Asia and Latin America—where brand loyalty and entrenched distribution sustain share.\u003c\/p\u003e\n\u003cp\u003eIt still nets nearly €1 billion in annual revenue with minimal operating costs; gross margins exceed 80% in mature markets, supplying steady, low-effort cash flow.\u003c\/p\u003e\n\u003cp\u003eSanofi channels these passive gains to fund its pivot to a pure-play biopharma, covering R\u0026amp;D investments and M\u0026amp;A financing for specialty assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual revenue: ~€1 billion\u003c\/li\u003e\n\u003cli\u003eGross margin: \u0026gt;80% in mature markets\u003c\/li\u003e\n\u003cli\u003eLow operating expense: minimal marketing\/production\u003c\/li\u003e\n\u003cli\u003eUse: funds R\u0026amp;D and biopharma M\u0026amp;A\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanofi’s 2025 cash cows (Lantus, Toujeo, IPV, Fabrazyme, Plavix) drive €6.2–6.5bn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLantus, Toujeo, IPV\/pertussis, Fabrazyme, and Plavix are Sanofi Cash Cows in 2025, together generating roughly €6.2–6.5bn in annual revenue and funding R\u0026amp;D, debt service, and a €10bn buyback program.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025 rev (€bn)\u003c\/th\u003e\n\u003cth\u003eMarket growth\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLantus\u003c\/td\u003e\n\u003ctd\u003e1.7+\u003c\/td\u003e\n\u003ctd\u003e0–1%\u003c\/td\u003e\n\u003ctd\u003eFund R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eToujeo\u003c\/td\u003e\n\u003ctd\u003e1.3+\u003c\/td\u003e\n\u003ctd\u003e0–1%\u003c\/td\u003e\n\u003ctd\u003eDebt\/buybacks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIPV\/pertussis\u003c\/td\u003e\n\u003ctd\u003e2.1 (2024)\u003c\/td\u003e\n\u003ctd\u003e1–2%\u003c\/td\u003e\n\u003ctd\u003eVaccine R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFabrazyme\u003c\/td\u003e\n\u003ctd\u003e1.1+\u003c\/td\u003e\n\u003ctd\u003e0–1%\u003c\/td\u003e\n\u003ctd\u003ePipeline funding\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlavix\u003c\/td\u003e\n\u003ctd\u003e~1.0\u003c\/td\u003e\n\u003ctd\u003e0–1%\u003c\/td\u003e\n\u003ctd\u003eLow‑effort cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eSanofi BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final Sanofi BCG Matrix you'll receive after purchase—no watermarks, no demo content, just a fully formatted, strategy-ready report built for clarity and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748215107961,"sku":"sanofi-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/sanofi-bcg-matrix.png?v=1772206153","url":"https:\/\/matrixbcg.com\/products\/sanofi-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}